Showing 683 results
-
Media Release /
-
Media Release /Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week 11 ULTIMATE is the first ever Phase IIIb…
-
Media Release /The STEP (Solutions to Empower Patients) ProgramTM supports nonprofit organizations that deliver creative solutions to address barriers to care Five patient advocacy organizations were provided…
-
Media Release /
-
Media Release /Results presented at the Migraine Trust Virtual Symposium highlight long-term benefit of Aimovig Aimovig has the longest duration of safety and efficacy trial data for any anti-CGRP pathway…
-
Media Release /
-
Media Release /Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice Commitment to include…
-
Media Release /
-
Media Release /Subgroup post hoc analysis of EXPAND reported that Mayzent reduced the risk of cognitive worsening and improved the chance of cognitive improvement at 6 months versus placebo in patients with…
-
Media Release /New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and prolonged time to…
